Current Cancer Clinical Trials
at DeKalb Medical
DeKalb Medical is currently participating in a number of cancer clinical trials. If you see an open trial below that you're interested in, please contact your physician. For additional trials that may be available to DeKalb Medical patients, please visit the Georgia Center for Oncology Research & Education (CORE) website.
This trial looks at the impact of lumpectomy, instead of mastectomy, on surgical and cosmetic outcomes in patients with multiple tumors in the same breast.
This study evaluates if there is a benefit to removing the breast tumor in cases where the breast cancer has already spread to other parts of the body.
A trial for breast patients with DCIS (a pre-cancerous condition, ductal carcinoma in situ) whose tumors express a protein on their cell surface called "Her-2." This trial studies whether or not there is better disease-free survival in patients who receive 2 doses of the drug Herceptin along with their radiation therapy for DCIS. Currently, Herceptin is not given to patients with DCIS.
This is a trial for women who have a low percentage of Her-2 overexpression in their breast cancer. This trial is seeking to answer the question of whether these women will also benefit from the addition of Herceptin to their course of therapy.
This is a trial for women who have breast cancer that has spread to their lymph nodes or high risk node-negative breast cancer. This trial is seeking to know whether anthracyclines can be removed from cancer treatment regimens without affecting survival. Anthracyclines are a class of chemotherapy drugs that are very effective, but also have harsh side effects.
This trial is designed to find out if radiation treatments to lymph nodes are still necessary if the lymph nodes no longer show cancer after chemotherapy. This is only for patients getting pre-operative chemotherapy.
This study is for patients who have been treated for colon cancer and are now disease-free. The study is designed to find out if treating these patients with a cholesterol-lowering drug (rosuvastatin) daily for five years reduces the risk of the cancer returning, or a new colon cancer or pre-cancerous polyps arising.
After chemotherapy for lung cancer, patients are often given maintenance chemotherapy with one of two drugs: Avastin® or Alimta®. This study compares maintenance therapy with each individual drug to maintenance with both drugs combined.
Two biologic therapies are often used along with chemotherapy in treating advanced lung cancer: Avastin® and Erbitux®. This study evaluates the benefit of adding Erbitux to chemotherapy with and without Avastin.
This trial compares treatment of smoldering (asymptomatic) myeloma with a drug called Revlimid to no treatment (i.e., observation, which is the current standard of care). The goal is to see if treatment delays the onset of symptomatic multiple myeloma.
For patients with pancreatic cancer who have already had chemotherapy, this study compares two new drugs, still under investigation, to a treatment regimen originally designed for colon cancer.
PROMISE and NBRST Tumor Registry Study
These studies incorporate MammaPrint, a 70-gene laboratory analysis of the participant's breast tumor. The test results are provided to the patient and her physician to help them plan her cancer treatment. The study is looking at whether this genetic evaluation will have an effect on treatment choices.
City of Hope Genetic Registry
Patients and their families are given the opportunity to take part in a confidential registry and blood and tissue repository to help identify a possible underlying predisposition to cancer. The study will help to answer questions about what role genetics and the environment play in a patient's risk for cancer.